Hospital Vithas La Salud

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Epilepsy8 trials
• Obesity3 trials
• Type 2 diabetes2 trials
• Prostate cancer1 trial

Phase

• Phase 37 trials
• Phase 23 trials
• Phase 2/32 trials

Status

• Active, not recruiting3 trials
• Recruiting3 trials
• Completed2 trials
• Not yet recruiting2 trials
• Terminated2 trials

Lead sponsor

• Eli Lilly and Company3 trials
• Praxis Precision Medicines Inc.3 trials
• Biohaven Therapeutics Ltd.2 trials
• Takeda2 trials
• Celgene1 trial
• and 1 more

Running trials

• Not yet recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

  NCT07900633· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes

  NCT07881458· Phase 3· Eli Lilly and Company· Source

  Contact: Cristobal Morales Portillo (principal investigator)

• Recruiting

  A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

  NCT07794579· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Open Label Extension Clinical Trial of Vormatrigine in Adult Patients with Epilepsy.

  2025-521640-38-00· Phase 3· Praxis Precision Medicines Inc.· Source

• Active, not recruiting

  A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

  NCT06764485· Phase 3· Celgene· Source

• Enrolling by invitation

  Long-term Safety and Tolerability of BHV-7000

  NCT06443463· Phase 2· Biohaven Therapeutics Ltd.· Source

• Active, not recruiting

  Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

  NCT06309966· Phase 2/3· Biohaven Therapeutics Ltd.· Source

• Active, not recruiting

  A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

  NCT03796962· Phase 2· Xenon Pharmaceuticals Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity3 recruiting
• Epilepsy2 recruiting
• Type 2 diabetes2 recruiting

Closed trials

• Completed

  A Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Seizures

  2025-524038-24-00· Phase 3· Praxis Precision Medicines Inc.· Source

• Completed

  A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults with Focal Seizures (POWER 1)

  2024-514559-13-00· Phase 2/3· Praxis Precision Medicines Inc.· Source

• Terminated

  A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome

  NCT05163314· Phase 3· Takeda· Source

• Terminated

  A Study of Soticlestat in Adults and Children With Rare Epilepsies

  NCT03635073· Phase 2· Takeda· Source